GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » PB Ratio

MediciNova (MediciNova) PB Ratio

: 1.21 (As of Today)
View and export this data going back to 2006. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-16), MediciNova's share price is $1.54. MediciNova's Book Value per Share for the quarter that ended in Dec. 2023 was $1.27. Hence, MediciNova's PB Ratio of today is 1.21.

The historical rank and industry rank for MediciNova's PB Ratio or its related term are showing as below:

MNOV' s PB Ratio Range Over the Past 10 Years
Min: 1.01   Med: 4   Max: 14.37
Current: 1.21

During the past 13 years, MediciNova's highest PB Ratio was 14.37. The lowest was 1.01. And the median was 4.00.

MNOV's PB Ratio is ranked better than
75.04% of 1310 companies
in the Biotechnology industry
Industry Median: 2.4 vs MNOV: 1.21

During the past 12 months, MediciNova's average Book Value Per Share Growth Rate was -11.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -7.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -5.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.80% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MediciNova was 92.10% per year. The lowest was -83.00% per year. And the median was -11.00% per year.

Back to Basics: PB Ratio


MediciNova PB Ratio Historical Data

The historical data trend for MediciNova's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.95 3.32 1.57 1.43 1.18

MediciNova Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.56 1.73 1.58 1.18

Competitive Comparison

For the Biotechnology subindustry, MediciNova's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MediciNova PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, MediciNova's PB Ratio distribution charts can be found below:

* The bar in red indicates where MediciNova's PB Ratio falls into.



MediciNova PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

MediciNova's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.54/1.272
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


MediciNova  (NAS:MNOV) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


MediciNova PB Ratio Related Terms

Thank you for viewing the detailed overview of MediciNova's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (MediciNova) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao director 4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a. officer: Chief Scientific Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr. officer: Chief Financial Officer 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda officer: Chief Medical Officer C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki director C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes officer: Chief Financial Officer 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi director 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien officer: Vice President 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037

MediciNova (MediciNova) Headlines

From GuruFocus